Perthera.ai at ASCO 2022
from June 4th to June 6th
ASCO meeting 2019
Genomic correlates of response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors.
ASCO Poster #110, Hall A, Saturday, June 4th, 8-11 AM
Session: Gastrointestinal Cancer-Gastroesophageal, Pancreatic and Hepatobiliary
We will be providing a demonstration of our RWE Analytics interface, which will allow you to take a deep dive into your curated data within the Perthera Oncology OS™ to pose real time clinical or research questions about specific biomarkers or to get better insights into clinical trial options personalized for your patients.
Stop by Booth 27102 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to experience our new RWE Analytics interface tool that advances data curation and trial selection; hear more about our ground-breaking research and collaborations; and meet the Perthera team, including our new President & CEO, Albert Kelley.
We will be on hand to introduce the new Perthera Oncology Operating System™ which empowers cancer care teams to prioritize molecularly-tailored therapies and eligibility-matched clinical trials with personalized insights powered by real-world evidence (RWE) and expert-in-the-loop Artificial Intelligence (AI).